Literature DB >> 27299462

Seropharmacological study on osteogenic effects of post-absorption ingredients of an osteoprotective herbal formula.

Wing-Sum Siu1,2,3, Chun-Hay Ko1,2, Hing-Lok Wong1,2, Si Gao1,2, Wai-Ting Shum1,2, Clara Bik-San Lau1,2, Lung-Kim Hung3, Ping-Chung Leung4,5,6.   

Abstract

OBJECTIVE: To further investigate the {ptin vitro} effects of an osteoprotective herbal formula "ELP" (Herba Epimedii, Fructus Ligustri Lucidi and Fructus Psoraleae) using seropharmacological approach.
METHODS: Rats were fed with ELP or its individual component herbs for 2 days. The serum containing the postabsorbed ingredients of the herbal items were collected for cell culture using UMR106 cell, RAW264.7 cell and mesenchymal stem cell (MSC) isolated from the bone marrow of the rats. The effects of the herbal-containing serum on cell toxicity were detected by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay; bromodeoxyuridine assay was conducted to measure the cell proliferation of UMR106 cell and MSC; cell activity was measured using colorimetric method, and mRNA expression of runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and osteopontin (OPN) of UMR106 and MSC as well as matrix metalloproteinase 9 (MMP-9), tartrate-resistant acid phosphatase (TRAP) and cathepsin K of RAW264.7 were analyzed using real-time reverse-transcription polymerase chain reaction.
RESULTS: ELP and its component serum exhibited no cytotoxic effects on the cells. The ELP-containing serum increased the proliferation of UMR106 cell and MSC by 25.7% and 14.4 %, respectively and the alkaline phosphatase activity of MSC was increased by 42.6%. On the contrary, it inhibited the RAW264.7 cell differentiation by 29.2 %. ELP serum upregulated the Runx2 expression of UMR and MSC by 1.18 fold and 1.27 fold, respectively. It also upregulated ALP and OPN expression in MSC by 1.69- and 2.12-fold, respectively. On the other hand, ELP serum down-regulated MMP-9 and cathepsin K expression of RAW264.7 cell by 0.46- and 0.36-fold, respectively.
CONCLUSIONS: The serum of the animals fed with ELP contains active ingredients which are effective in promoting osteogenesis and inhibiting osteoclastogenesis.

Entities:  

Keywords:  herbal formula; osteogenesis; osteoporosis; seropharmacology

Mesh:

Substances:

Year:  2016        PMID: 27299462     DOI: 10.1007/s11655-016-2474-5

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  40 in total

Review 1.  Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling.

Authors:  Lei-Guo Ming; Ke-Ming Chen; Cory J Xian
Journal:  J Cell Physiol       Date:  2013-03       Impact factor: 6.384

2.  Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice.

Authors:  Wen-Fang Chen; Sao-Keng Mok; Xin-Luan Wang; Ka-Hang Lai; Wan-Ping Lai; Hon-Kit Luk; Ping-Chung Leung; Xin-Sheng Yao; Man-Sau Wong
Journal:  Br J Nutr       Date:  2010-09-06       Impact factor: 3.718

3.  Bioactivity-guided Isolation of antiosteoporotic compounds from Ligustrum lucidum.

Authors:  Qianfeng Chen; Lijuan Yang; Guolin Zhang; Fei Wang
Journal:  Phytother Res       Date:  2012-08-15       Impact factor: 5.878

Review 4.  Osteoporosis management in post-menopausal women.

Authors:  E S Christenson; X Jiang; R Kagan; P Schnatz
Journal:  Minerva Ginecol       Date:  2012-06

5.  Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells.

Authors:  Sao-Keng Mok; Wen-Fang Chen; Wan-Ping Lai; Ping-Chung Leung; Xin-Luan Wang; Xin-Sheng Yao; Man-Sau Wong
Journal:  Br J Pharmacol       Date:  2010-01-27       Impact factor: 8.739

Review 6.  Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.

Authors:  Emily E Sutton; Daniel M Riche
Journal:  Ann Pharmacother       Date:  2012-07-25       Impact factor: 3.154

7.  Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine.

Authors:  Wing I Cheung; Man Li Tse; Teresa Ngan; Jieru Lin; Ws Ken Lee; Wing Tat Poon; Tony Wl Mak; Vincent King Sun Leung; Tai Nin Chau
Journal:  Clin Toxicol (Phila)       Date:  2009-08       Impact factor: 4.467

8.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

9.  Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety.

Authors:  Chad L Deal; Michael W Draper
Journal:  Womens Health (Lond)       Date:  2006-03

10.  Effect of shosaikoto, a Japanese and Chinese traditional herbal medicinal mixture, on the mitogenic activity of lipopolysaccharide: a new pharmacological testing method.

Authors:  H Iwama; S Amagaya; Y Ogihara
Journal:  J Ethnopharmacol       Date:  1987 Sep-Oct       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.